Skip to content

Homeopathic treatment of skin disease in children

Treatment of molluscum contagiosum with individualized homoeopathic medicines for three months in children and adolescents: Double-blind, randomized, placebo-controlled trial

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050821
Enrollment
140
Registered
2023-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B081- Molluscum contagiosum

Interventions

i.e., not to scratch the lesions, avoid the sharing of garments and linen, wash the infected clothes and bed linen separately in hot water, and avoid bathing with siblings and the use of swimming pool
dosage and repetition depending upon the individual requirement of the cases. All sundry items will be procured from a Good Manufacturing Practice (GMP) certified firm. All the enrolled patients will
i.e., not to scratch the lesions, avoid the sharing of garments and linen, wash the infected clothes and bed line

Sponsors

D N De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from MC (B08.1), diagnosis by naked eye examination and confirmation by dermatologist 2. Age between 2 and 18 years 3. Number of lesions between 6 and 15 4. Patients of either sex 5. Literate patients; able to read English and/or Bengali and/or Hindi while illiterate people will be interviewed by the investigators maintaining adequate privacy to fill up the scales or questionnaires. 6. Providing written informed assent and/or consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Cases with secondary bacterial infection, as confirmed by CBC, CRP and examined by the Dermatologist. 2. Cases with involvement of mucosal surfaces, especially conjunctiva resulting in conjunctivitis and keratitis, and other atypical sites such as oral mucosa, palms and soles, the areola/nipple, lips, eyelids. 3. Size of lesions more than 5 mm 4. Cases with extensive or giant (more than 1 cm) and pedunculated lesions. 5. Patients showing BOTE sign. 6. Patients having history of congenital transmission. 7. Vulnerable population - too sick for consultation, unconscious, non-ambulatory, differently abled, terminally ill, or critically ill patients, mentally incompetent people. 8. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure. 9.Patient under tobacco chewing and/or smoking, alcoholism and/or any other form(s) of substance abuse and/or dependence. 10. Self-reported immune-compromised state. 11. Already undergoing homeopathic treatment for chronic disease within last 6 months. 12. Simultaneous participation in any other clinical trial

Design outcomes

Primary

MeasureTime frame
Lesion countsTimepoint: At baseline, every 15 days, up to 3 months

Secondary

MeasureTime frame
Average cumulative diameter of the lesions Timepoint: At baseline, every 15 days, up to 3 months;Childrens Dermatology Life Quality Index questionnaireTimepoint: At baseline, every 15 days, up to 3 months;Dermatology Life Quality Index questionnaireTimepoint: At baseline, every 15 days, up to 3 months;Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) scoresTimepoint: At baseline, every 15 days, up to 3 months;Occurrence of adverse eventsTimepoint: At baseline, every 15 days, up to 3 months;Time taken (counted in days) in disappearance of the lesionsTimepoint: At baseline, every 15 days, up to 3 months

Countries

India

Contacts

Public ContactArpita Basu

D N De Homoeopathic Medical College and Hospital

drarpitasen@gmail.com9830273374

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026